Vyvanse is amphetamine with a chaperone. The molecule you swallow, lisdexamfetamine, has an amino acid (lysine) stapled onto a regular d-amphetamine. In that form it does basically nothing. It has to get to your red blood cells, where an enzyme slowly clips the lysine off, and only then do you have free amphetamine in circulation. That’s the whole trick. Everything interesting about how Vyvanse feels and how it doses out comes from that one piece of chemistry.
The practical consequence is that the curve is smooth. There’s no IR-style peak at ninety minutes and no obvious cliff four hours later. The enzymatic conversion paces the release on its own, and it paces it pretty consistently from person to person. You get a long, gentle ramp, a long plateau, and a slow taper. Ten to fourteen hours of working medication for most people, depending on dose and metabolism.
It’s a Schedule II amphetamine prodrug, FDA-approved for ADHD in 2007 and for binge eating disorder in 2015. The BED indication is the one most patients have never heard of, and it’s the one I want to get to later in this post, because it changes who Vyvanse is for.
Why the prodrug delay actually matters
People sometimes hear “prodrug” and assume it’s marketing. It isn’t. The lysine doesn’t come off until the molecule hits the bloodstream and meets the right peptidase. You can’t snort it, you can’t shoot it, you can’t crush it and chew it for a faster hit. The enzymatic step is the rate-limiter, and the enzyme doesn’t care what route you took. The abuse liability isn’t zero, but the euphoric peak that drives most amphetamine misuse is significantly blunted because there’s no sharp spike to chase.
That same blunting is what most ADHD patients actually want. With Vyvanse most people don’t feel a “kick-in” moment. They notice an hour or two in that they’ve been working on the same task without getting up, and that’s the medication. The lack of a felt onset is, for a lot of patients, the whole appeal. They wanted treatment, not a drug experience.
The “I miss my Adderall IR” patient
I had a software engineer last spring, late thirties, on Adderall IR 20mg twice a day for six years. Productive, well-controlled, but the cycle was getting to him. First dose at 7 AM, kick in around 8:30, ride until noon, crash through lunch, second dose at 12:30, ride to five, crash through the evening. He wanted off the rollercoaster. We converted him to Vyvanse 50mg.
Three weeks in he came back unhappy. The medication “wasn’t working.” When we got into it, what he meant was that he couldn’t feel it. He’d been using the IR kick as his internal signal that he was now in work mode. Without that, he was sitting at his desk at 9 AM waiting for something to happen, and when nothing did, he assumed the medication had failed. We pulled his task data. He’d actually shipped more code in those three weeks than in the previous month. The medication was working fine… what had failed was his ritual.
That’s the most common version of the Vyvanse-disappointment story. If your IR doses were also functioning as a structuring cue, the smooth release is going to feel like nothing for the first month while your brain rebuilds the cue. Most people get past it. Some don’t, and end up back on IR.
The lack of a felt onset is, for a lot of patients, the whole appeal. They wanted treatment, not a drug experience.
Conversion math and dosing strategy
The rough conversion most psychiatrists use is that 30mg of Vyvanse is in the ballpark of 10mg of mixed amphetamine salts, 50mg is in the ballpark of 15-20mg, and 70mg is in the ballpark of 25-30mg of total daily Adderall. It’s rough. Individual variability is real, and the comparison isn’t apples to apples because IR doses pulse and Vyvanse doesn’t. I usually start adults at 30mg, hold for a week, and titrate up by 10 or 20mg at a time. Most adults land between 50 and 70mg. Seventy is the FDA ceiling. I have very few patients who genuinely need more, and when I do, I’d rather augment with a small IR dose in the late afternoon than chase a higher prodrug load.
10 to 14 hours
Plan to take it before 9 AM. Take it at noon and you’ll be staring at your ceiling at midnight. The enzymatic release doesn’t care what your schedule looks like.
30 to 70mg
Adults usually land at 50 or 70mg. Start at 30. Move by 10 to 20mg every week or two. Seventy is the FDA cap for ADHD. Same cap for BED.
Prodrug, not pill
The release isn’t controlled by a coating or a pump. Your red blood cells do the work. That’s why the curve is smoother than Adderall XR for almost everybody.
About the afternoon crash question. People ask me constantly whether Vyvanse crashes. It tapers more gently than IR amphetamines, which most patients describe as “no crash” or “barely any crash.” Maybe one in five still get a real afternoon dip around hour ten or eleven, usually irritability and brain fog rather than the full IR-style collapse. The fix is either a small IR booster (5mg of dextroamphetamine at 3 PM) or accepting the dip and structuring the evening around it. I lean toward the second when I can. Stacking a short-acting on top of a long-acting starts to add up to a lot of total amphetamine.
Binge eating disorder, which most patients have never heard of
This is the indication that gets missed, and missing it costs people years of suffering. Vyvanse is the only FDA-approved medication for binge eating disorder in adults. Appetite does drop on it, but the cheap stimulant appetite-suppression story doesn’t explain what’s happening. The mechanism appears to be the same impulse-control and reward-modulation work the drug does for ADHD, applied to the eating loop. Patients with BED report fewer binge episodes, smaller binges when they happen, and longer gaps between them. The effect shows up at the 50 to 70mg range, similar to the ADHD dosing.
I had a woman come in two years ago for what she thought was depression. Mid-forties, weight had been climbing for a decade, mood was awful. We talked about her eating and it was textbook BED: late-night binges three or four nights a week, eating until physically uncomfortable, then shame, then promising herself she’d be “good” tomorrow, then doing it again forty-eight hours later. She’d been to two therapists and a nutritionist. Nobody had named it. We started Vyvanse at 30, titrated to 50, and within two months her binge frequency had dropped to maybe twice a month and was continuing to fall. The depression, which had been driven mostly by the shame loop around the bingeing, lifted on its own. She didn’t have a primary depression. She had untreated BED for fifteen years, and her mood was downstream of the loop.
If you’re reading this and any of that sounds familiar, ask your prescriber whether you have a binge pattern, and whether anybody has actually screened you for it. Most clinicians don’t ask. You usually have to bring it up yourself.
Why some patients prefer it over Concerta
Concerta is a fine long-acting methylphenidate. The osmotic pump gives you a reasonable workday of coverage, eight to twelve hours. Vyvanse pulls ahead for some patients because the curve is smoother in the back half of the day (no mechanical pump to empty at a predictable rate), and because a subset of patients who didn’t respond to methylphenidate respond fine to amphetamine and vice versa.
That doesn’t make Vyvanse the right starting medication for everybody. For kids and adolescents I usually start with methylphenidate because the appetite suppression is less of a growth issue. For adults with clean ADHD and no cardiovascular flags, I’ll start with Vyvanse more often than not. For adults with a binge pattern, Vyvanse moves to the front of the line regardless of whether they call the binge pattern a problem yet.
The prodrug design isn’t magic and it isn’t risk-free. It’s a Schedule II amphetamine and it deserves the same respect any Schedule II gets. But the smoothness it buys you, and the BED indication nobody talks about, are the reasons it’s the long-acting stimulant I reach for first in most adults.